The original success of the copyright undeniably transformed the pharmaceutical landscape, but betting in companies primarily reliant on generic versions presents a complex picture. While early earnings were impressive, the cessation of patents and the emergence of cheaper alternatives have eroded sales. Therefore, a thorough assessment of ongoing